Appropriate Targets for Antibacterial Drugs
- PMID:27599531
- PMCID: PMC5131749
- DOI: 10.1101/cshperspect.a030239
Appropriate Targets for Antibacterial Drugs
Abstract
Successful small-molecule antibacterial agents must meet a variety of criteria. Foremost is the need for selectivity and safety: It is easy to kill bacteria with chemicals, but difficult to do it without harming the patient. Other requirements are possession of a useful antibacterial spectrum, no cross-resistance with existing therapeutics, low propensity for rapid resistance selection, and pharmacological properties that allow effective systemic dosing. Choosing molecular targets for new antibiotics does seem a good basis for achieving these criteria, but this could be misleading. Although the presence of the target is necessary to insure the desired spectrum, it is not sufficient, as the permeability and efflux properties of various species, especially Gram-negatives, are critical determinants of antibacterial activity. Further, although essentiality (at least in vitro), lack of close human homologs, lack of target-based cross-resistance, and presence in important pathogens can be predicted based on the target, the choice of a single enzyme as a target may increase the likelihood of rapid resistance selection. In fact, it is likely that the low output of antibacterial target-based discovery is because of difficulty of endowing lead enzyme inhibitors with whole-cell activity and to the propensity for such inhibitors (if they can gain entry) to select rapidly for resistance. These potential problems must be reckoned with for success of novel target-based discovery.
Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.
Similar articles
- [The history of the development and changes of quinolone antibacterial agents].Takahashi H, Hayakawa I, Akimoto T.Takahashi H, et al.Yakushigaku Zasshi. 2003;38(2):161-79.Yakushigaku Zasshi. 2003.PMID:15143768Japanese.
- Novel Antibacterial Compounds and their Drug Targets - Successes and Challenges.Kaczor AA, Polski A, Sobótka-Polska K, Pachuta-Stec A, Makarska-Bialokoz M, Pitucha M.Kaczor AA, et al.Curr Med Chem. 2017;24(18):1948-1982. doi: 10.2174/0929867323666161213102127.Curr Med Chem. 2017.PMID:27978802Review.
- Emerging bacterial enzyme targets.Su Z, Honek JF.Su Z, et al.Curr Opin Investig Drugs. 2007 Feb;8(2):140-9.Curr Opin Investig Drugs. 2007.PMID:17328230Review.
- Leveraging structural information for the discovery of new drugs: computational methods.Nguyen TB, Wong SE, Lightstone FC.Nguyen TB, et al.Methods Mol Biol. 2012;841:209-34. doi: 10.1007/978-1-61779-520-6_9.Methods Mol Biol. 2012.PMID:22222454
- 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.Ellsworth EL, Tran TP, Showalter HD, Sanchez JP, Watson BM, Stier MA, Domagala JM, Gracheck SJ, Joannides ET, Shapiro MA, Dunham SA, Hanna DL, Huband MD, Gage JW, Bronstein JC, Liu JY, Nguyen DQ, Singh R.Ellsworth EL, et al.J Med Chem. 2006 Nov 2;49(22):6435-8. doi: 10.1021/jm060505l.J Med Chem. 2006.PMID:17064062
Cited by
- In Vitro Study of Biological Activity ofTanacetum vulgare Extracts.Babich O, Larina V, Krol O, Ulrikh E, Sukhikh S, Gureev MA, Prosekov A, Ivanova S.Babich O, et al.Pharmaceutics. 2023 Feb 12;15(2):616. doi: 10.3390/pharmaceutics15020616.Pharmaceutics. 2023.PMID:36839938Free PMC article.
- β-Lactams against the Fortress of the Gram-PositiveStaphylococcus aureus Bacterium.Fisher JF, Mobashery S.Fisher JF, et al.Chem Rev. 2021 Mar 24;121(6):3412-3463. doi: 10.1021/acs.chemrev.0c01010. Epub 2020 Dec 29.Chem Rev. 2021.PMID:33373523Free PMC article.Review.
- Antibiotics targeting bacterial ribosomal subunit biogenesis.Champney WS.Champney WS.J Antimicrob Chemother. 2020 Apr 1;75(4):787-806. doi: 10.1093/jac/dkz544.J Antimicrob Chemother. 2020.PMID:31942624Free PMC article.Review.
- In Vitro Assessment of the Combination of Antibiotics against Some Integron-Harbouring Enterobacteriaceae from Environmental Sources.Fadare FT, Elsheikh EAE, Okoh AI.Fadare FT, et al.Antibiotics (Basel). 2022 Aug 11;11(8):1090. doi: 10.3390/antibiotics11081090.Antibiotics (Basel). 2022.PMID:36009959Free PMC article.
- Synthesis of Fusidic Acid Derivatives Yields a Potent Antibiotic with an Improved Resistance Profile.Garcia Chavez M, Garcia A, Lee HY, Lau GW, Parker EN, Komnick KE, Hergenrother PJ.Garcia Chavez M, et al.ACS Infect Dis. 2021 Feb 12;7(2):493-505. doi: 10.1021/acsinfecdis.0c00869. Epub 2021 Feb 1.ACS Infect Dis. 2021.PMID:33522241Free PMC article.
References
- Black T, Hare R. 2000. Will genomics revolutionize antimicrobial drug discovery? Curr Opin Microbiol 3: 522–527. - PubMed
- Brotz-Oesterhelt H, Brunner NA. 2008. How many modes of action should an antibiotic have? Curr Opin Pharmacol 8: 564–573. - PubMed
- Brown DG, May-Dracka TL, Gagnon MM, Tommasi R. 2014. Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. J Med Chem 57: 10144–10161. - PubMed
- Chan PF, Macarron R, Payne DJ, Zalacain M, Holmes DJ. 2002. Novel antibacterials: A genomics approach to drug discovery. Curr Drug Targets Infect Disord 2: 291–308. - PubMed
- Chopra I. 2012. The 2012 Garrod Lecture: Discovery of antibacterial drugs in the 21st century. J Antimicrob Chemother 68: 496–505. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical